MiRNA | Most recent annotation* | Accession number | Disease stage | Smoker vs never-smoker | COPD vs smoker | COPD vs never-smoker | Increasing emphysema severity | Tissue/cell-type | Targets | References |
---|---|---|---|---|---|---|---|---|---|---|
COPD | ||||||||||
miR-218 | hsa-miR-218–5p | MIMAT0000275 | no COPD | ↓ | Bronchial airway epithelium | MAFG (validated) | 17 | |||
GOLD I and II | ↓ | ↓ | Induced sputum | 10 | ||||||
GOLD I to IV | ↓ | BAL fluid | 18 | |||||||
miR-146a | hsa-miR-146a-5p | MIMAT0000449 | GOLD I to IV | ↓ | Fibroblasts | COX-2 (predicted) | 33 | |||
GOLD I and II | ↓ | ↓ | ↓ | Induced sputum | 10 | |||||
GOLD I, II and IV | ↑ | Lung tissue | 27 | |||||||
let-7c | hsa-let-7c-5p | MIMAT0000064 | GOLD I and II | ↓ | ↓ | ↓ | Induced sputum | TNFR-II (predicted) | 10 | |
miR-101 | hsa-miR-101-3p | MIMAT0000099 | GOLD IV | ↑† | Lung tissue | CFTR (validated), MPK-1 (predicted) | 44 | |||
miR-15b | hsa-miR-15b-5p | MIMAT0000417 | GOLD I, II and IV | ↑ | Lung tissue | SMAD7 (validated) | 27 | |||
miR-144 | hsa-miR-144-3p | MIMAT0000436 | GOLD I, II and IV | ↑ | Lung tissue | CFTR (validated) | 27 | |||
miR-199a-5p | hsa-miR-199a-5p | MIMAT0000231 | not specified | ↓† | Peripheral blood monocytes | ATF6, NF-κB1,RELA, GRP78, IRE1, HIF-1α (validated) | 49 | |||
GOLD I to IV | ↑ | Lung tissue | 57 | |||||||
GOLD I to IV | ↓ | T-regulatory cells | 50 | |||||||
miR-34b | hsa-miR-34b-3p | MIMAT0004676 | GOLD I and II | ↓ | ↓ | Induced sputum | 10 | |||
miR-452 | hsa-miR-452-5p | MIMAT0001635 | No COPD | ↓ | Alveolar macrophages | MMP12 (predicted) | 23 | |||
miR-34c | hsa-miR-34c-5p | MIMAT0000686 | GOLD I and II | ↓ | ↓ | Induced sputum | 10 | |||
Emphysema | ||||||||||
miR-34c | hsa-miR-34c-5p | MIMAT0000686 | GOLD I and II: Mild versus moderate emphysema (measured by KCO) | ↓ | Lung tissue | 63 | ||||
miR-638 | hsa-miR-638 | MIMAT0003308 | GOLD IV (measured by Lm on CT) | ↑ | Lung tissue | 52 |
*MiRBase release 21.
†Patients with COPD were compared with controls (the article does not specify whether the controls were smokers or non-smokers).
ATF6, activation of transcription factor 6; BAL, bronchoalveolar lavage; CFTR, cystic fibrosis transmembrane conductance regulator; COX-2, cyclooxygenase-2; GOLD, Global Initiative for Chronic Obstructive Pulmonary Disease; GRP78, glucose response protein 78; HIF-1α, hypoxia inducible factor 1α; IRE1, inositol requiring enzyme 1α; KCO, lung carbon monoxide transfer coefficient; Lm, mean linear intercept; MAFG, v-maf musculoaponeurotic fibrosarcoma oncogene homologue G, avian; miR, microRNA; MMP-12, matrix metallopeptidase 12; MPK-1, mitogen-activated protein kinase phosphatase 1; NF-κB1, nuclear factor κB1; RELA, V-Rel avian reticuloendotheliosis viral oncogene homologue A; SMAD7, mothers against decapentaplegic homologue 7; TNFR-II, tumour necrosis factor receptor II.